OBJECTIVES: To investigate the pharmacokinetics (PK) of maraviroc, a CCR5-targeted HIV-1 entry inhibitor, in rhesus macaques following vaginal administration of various maraviroc-loaded aqueous hydroxyethylcellulose (HEC) gels, and to correlate the PK data with efficacy in a single high-dose vaginal SHIV-162P3 challenge model. METHODS: Maraviroc concentrations in vaginal fluid (Weck-Cel(®) sponge), vaginal tissue (punch biopsy) and plasma were assessed over 72 h following single-dose vaginal application of various maraviroc-loaded HEC gels. The range of maraviroc gel concentrations was sufficiently broad (0.003%-3.3% w/w) that test gels included both fully solubilized and predominantly dispersed formulations. The efficacy of the HEC gels against a single high-dose vaginal SHIV-162P3 challenge was also measured, and correlated with the PK concentrations. RESULTS: Maraviroc concentrations in vaginal fluid (range 10(4)-10(7) ng/mL), vaginal tissue (100-1200 ng/g) and plasma (<10(2) ng/mL) were highly dependent on maraviroc gel loading, irrespective of the form of the maraviroc component within the gel (solubilized versus dispersed). Fluid and plasma concentrations were generally highest 0.5 or 2 h after gel application, before declining steadily through to 72 h. Maraviroc concentrations in the various biological compartments correlated strongly with the extent of protection against vaginal SHIV-162P3 challenge. Complete protection was achieved with a 3.3% w/w maraviroc gel. CONCLUSIONS: A high degree of correlation between PK and efficacy was observed. Based on the data obtained with the 3.3% w/w maraviroc gel, maintenance of vaginal fluid and tissue levels in the order of 10(7) ng/mL and 10(3) ng/g, respectively, are required for complete protection with this compound.
OBJECTIVES: To investigate the pharmacokinetics (PK) of maraviroc, a CCR5-targeted HIV-1 entry inhibitor, in rhesus macaques following vaginal administration of various maraviroc-loaded aqueous hydroxyethylcellulose (HEC) gels, and to correlate the PK data with efficacy in a single high-dose vaginal SHIV-162P3 challenge model. METHODS: Maraviroc concentrations in vaginal fluid (Weck-Cel(®) sponge), vaginal tissue (punch biopsy) and plasma were assessed over 72 h following single-dose vaginal application of various maraviroc-loaded HEC gels. The range of maraviroc gel concentrations was sufficiently broad (0.003%-3.3% w/w) that test gels included both fully solubilized and predominantly dispersed formulations. The efficacy of the HEC gels against a single high-dose vaginal SHIV-162P3 challenge was also measured, and correlated with the PK concentrations. RESULTS: Maraviroc concentrations in vaginal fluid (range 10(4)-10(7) ng/mL), vaginal tissue (100-1200 ng/g) and plasma (<10(2) ng/mL) were highly dependent on maraviroc gel loading, irrespective of the form of the maraviroc component within the gel (solubilized versus dispersed). Fluid and plasma concentrations were generally highest 0.5 or 2 h after gel application, before declining steadily through to 72 h. Maraviroc concentrations in the various biological compartments correlated strongly with the extent of protection against vaginal SHIV-162P3 challenge. Complete protection was achieved with a 3.3% w/w maraviroc gel. CONCLUSIONS: A high degree of correlation between PK and efficacy was observed. Based on the data obtained with the 3.3% w/w maraviroc gel, maintenance of vaginal fluid and tissue levels in the order of 10(7) ng/mL and 10(3) ng/g, respectively, are required for complete protection with this compound.
Authors: Maria C Rosario; Philippe Jacqmin; Pat Dorr; Elna van der Ryst; Chris Hitchcock Journal: Clin Pharmacol Ther Date: 2005-09-28 Impact factor: 6.875
Authors: Ronald S Veazey; Per Johan Klasse; Susan M Schader; Qinxue Hu; Thomas J Ketas; Min Lu; Preston A Marx; Jason Dufour; Richard J Colonno; Robin J Shattock; Martin S Springer; John P Moore Journal: Nature Date: 2005-10-30 Impact factor: 49.962
Authors: Don K Walker; Samantha Abel; Pierre Comby; Gary J Muirhead; Angus N R Nedderman; Dennis A Smith Journal: Drug Metab Dispos Date: 2005-01-13 Impact factor: 3.922
Authors: Ronald S Veazey; Martin S Springer; Preston A Marx; Jason Dufour; Per Johan Klasse; John P Moore Journal: Nat Med Date: 2005-11-06 Impact factor: 53.440
Authors: Pedro M M Mesquita; Rachna Rastogi; Theodore J Segarra; Ryan S Teller; N Merna Torres; Ashley M Huber; Patrick F Kiser; Betsy C Herold Journal: J Antimicrob Chemother Date: 2012-03-30 Impact factor: 5.790
Authors: R Karl Malcolm; Deborah Lowry; Peter Boyd; Leslie Geer; Ronald S Veazey; Laurie Goldman; P J Klasse; Robin J Shattock; John P Moore Journal: J Antimicrob Chemother Date: 2013-12-30 Impact factor: 5.790
Authors: Corrine Ying Xuan Chua; Priya Jain; Andrea Ballerini; Giacomo Bruno; R Lyle Hood; Manas Gupte; Song Gao; Nicola Di Trani; Antonia Susnjar; Kathryn Shelton; Lane R Bushman; Marco Folci; Carly S Filgueira; Mark A Marzinke; Peter L Anderson; Ming Hu; Pramod Nehete; Roberto C Arduino; Jagannadha K Sastry; Alessandro Grattoni Journal: J Control Release Date: 2018-08-06 Impact factor: 9.776
Authors: Claire J Forbes; Clare F McCoy; Diarmaid J Murphy; A David Woolfson; John P Moore; Abbey Evans; Robin J Shattock; R Karl Malcolm Journal: J Pharm Sci Date: 2014-03-01 Impact factor: 3.534
Authors: John A Moss; Priya Srinivasan; Thomas J Smith; Irina Butkyavichene; Gilbert Lopez; Amanda A Brooks; Amy Martin; Chuong T Dinh; James M Smith; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2014-06-16 Impact factor: 5.191